
## EXHIBIT G

The declaration of the fake CSO of Sunomix in proposal for award 1R01AI150091 (pages 11, 61, and 73).

Contact PD/PI: BENMOHAMED, LBACHIR



Contact PD/PI: BENMOHAMED, LBACHIR

OMB Number: 4040-0001 Expiration Date: 10/31/2019

RESEARCH & RELATED BUDGET - SECTION A & B, Budget Period 1

ORGANIZATIONAL DUNS\*: 080437688

Budget Type\*: ○ Project ● Subaward/Consortium

Enter name of Organization: Sunomix Therapeutics Inc

| A. Senior/Key Person    |               |                   |   |             |          |          |        |              |                |                       |
|-------------------------|---------------|-------------------|---|-------------|----------|----------|--------|--------------|----------------|-----------------------|
| Prefix First Name*      | Middle        | Last Name*        | Suffix Project Role*                    | Base        | Calendar | Academic | Summer | Requested    | Fringe         | Funds Requested (\$)* |
|                         | Name          |                   |   | Salary (\$) | Months   | Months   | Months | Salary (\$)* | Benefits (\$)* |                       |
| 1. Peter                |               | Burkhard          | Consortium<br>Principal<br>Investigator | 189,600.00  | 1.2      |          |        | 18,960.00    | 4,930.00       | 23,890.00             |
| Total Funds Requested   | for all Senic | or Key Persons in | the attached file                       |             |          |          |        |              |                |                       |
| Additional Senior Key P | ersons:       | File Name:        |   |             |          |          |        | Total Seni   | or/Key Person  | 23.890.00             |

Contact PD/PI: BENMOHAMED, LBACHIR

## **BUDGET JUSTIFICATION**

Sunomix Therapeutics, San Diego, CA

Year 1: Direct Cost: \$81,900, Indirect cost: 0; Total Cost: \$81,900 Year 2: Direct Cost: \$81,900, Indirect cost: 0; Total Cost: \$81,900

## **PERSONNEL:**

Peter Burkhard, Ph.D., Principal Investigator 1.2 Calendar Months

\$ 47,780

Dr. Burkhard will be directly involved in the design, development, cloning, protein expression, purification, refolding, TLR-activation and analysis of the gD, VP16, VP22 RR1 or RR2 proteins-based SAPNs. The prototypes will be send to Sunomix for scale up production. 10% salary at NIH cap with 26% benefit rate is budgeted for the PI.

The declaration of the fake CSO of Sunomix in proposal for award 1R01AI158060 (pages 15, 93, and 107).

Contact PD/PI: BENMOHAMED, LBACHIR

PROFILE - Senior/Key Person Prefix: First Name\*: Peter Middle Name Last Name\*: Burkhard Suffix: Position/Title\*: Chief Scientific Office Organization Name\*: Sunomix Therapeutics Department: Division: Street1\* 3210 Merryfield Row Street2: City\*: San Diego County: CA: California State\* Province: Country\*: **USA: UNITED STATES** Zip / Postal Code\*: 92130-5602 Phone Number\*: 858-829-6063 Fax Number: 858-900-5059 E-Mail\*: pburkhard@sunomixtherapeutics.com Credential, e.g., agency login: PETERBURKHARD Project Role\*: Other (Specify) Other Project Role Category: Consortium PI Degree Type: Ph.D. Degree Year: 1995 Attach Biographical Sketch\*: File Name: 2\_Burkhard\_Bio1013860968.pdf Attach Current & Pending Support: File Name

Contact PD/PI: BENMOHAMED, LBACHIR

BUDGET JUSTIFICATION Sunomix Therapeutics, San Diego, CA UCI Grant R01 Titled: Developing a Multi-epitope Pan-Co UCI PI: Dr Lbachir Benmohamed

Year 1: \$114,545.00 Direct Cost + \$11,455.00 Indirect Cost (10%) Total Cost \$126,000.00 Year 2: \$114,545.00 Direct Cost + \$11,455.00 Indirect Cost (10%) Total Cost \$126,000.00

We are requesting a total cost budget over 2 years duration of \$ 252,000,00

Year 1: \$114.545.00 Direct Cost + \$11.455.00 Indirect Cost (10%) Total Cost \$126.000.00

PERSONNEL:

Peter Burkhard, Ph. D. Consortium PI < 0.1 Calendar Months

Dr. Burkhard, a specialist in SAPNs nanoparticles will devote effort as needed will help design and produce SAPN-based vaccines as described in this proposal.

## **INVESTIGATORS**

This application gathers a multidisciplinary team of ten top scientists and clinicians who have complementary expertise in different areas of vaccine development. These include: (1) The Principal Investigator (Dr. Lbachir BenMohamed, UC Irvine), an immune-virologist and vaccinologist with over 30 years of experience in the area of viral infection/immunity and vaccine development; (2) A virologist and a world authority in Coronavirus infections (<u>Dr. Michael Buchmeier</u> UC Irvine). <u>Dr. Buchmeier brings to the project more than 35 years of experience with the Coronaviruses including SARS-CoV.</u> We expect the daily interaction between Dr. BenMohamed, an immunologist, and Dr. Buchmeier, a Coronavirus expert and an active co-investigator on this vaccine to speed analyzing and correlating the immunological and virological results (both labs are located side-by-side at UC Irvine). Dr. Buchmeier has published a number of seminal discoveries on SARS-CoV infections<sup>[146-152]</sup>. (3) An expert in clinical infectious diseases (Dr. Anthony B. Nesburn, UC Irvine); (4) A biostatistician (Dr. Christine McLaren, UC Irvine); (5) An expert in inflammation and cytokine storm (Dr. Eric Pearlman, Director, UC Irvine Institute for Immunology); (6) An expert in advanced microscopic imaging (Dr. James V. Jester, UC Irvine); (7) An expert in SAPNs-based vaccine design and production (Dr. Peter Burkhard, Sunomix Therapeutics, Inc., San Diego). The collaborative project also includes three physicians and clinicians, (8) Dr. Donald Forthal; (9) Dr. Sebastian Schubl, and (10) Dr. Lanny Hsieh all located at UCl's COVID-19 Research Biobank and Biorepository, that help identify COVID-19 patients.